Plain-English translation of NCT06494540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that collects real-world data from patients receiving a combination treatment called tremelimumab, durvalumab, and platinum chemotherapy for advanced non-squamous lung cancer. Researchers want to understand how well this medication works in different patients, especially those with specific genetic changes in their cancer cells. Your medical information and treatment outcomes will help doctors learn who benefits most from this approach.
Current treatment guidelines recommend this three-drug combination for certain lung cancer patients, but doctors need more real-world information about how it actually performs in everyday practice. By studying genetic patterns in patients' tumors alongside treatment results, researchers hope to identify which patients are most likely to benefit and develop better, more personalized treatment strategies.
You likely qualify if…
You likely don't qualify if…
This is not an interventional study — you will not receive the medication through this trial. Instead, your doctor will prescribe the treatment as normal, and researchers will collect information from your medical records about how you respond, including blood work, imaging results, and genetic test findings. You will likely have regular clinic visits as part of your standard cancer care, and the study team will track your progress over time to understand how the treatment works for patients with your specific cancer characteristics.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Germany